Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aegerion Pharmaceuticals, Inc. (AEGR)

NEW YORK, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") AEGR in the United States District Court for the District of Massachusetts on behalf of current stock holders of Aegerion, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act").

On June 14, 2016, Aegerion's Board of Directors (the "Board") caused the Company to enter into an agreement and plan of merger (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of Parent common stock. The Complaint alleges that on August 8, 2016, Defendants issued materially incomplete and misleading disclosures in the Form S-4 Registration Statement (the "Registration Statement") filed with the United States Securities and Exchange Commission ("SEC") in connection with the Proposed Transaction. The Registration Statement is deficient and misleading in that it fails to provide adequate disclosure of all material information related to the Proposed Transaction.

If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.

Please visit our website at http://www.gme-law.com for more information about the firm.